

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

U.S. PATENTS							<a href="#">Remove</a>	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							<a href="#">Add</a>	
U.S. PATENT APPLICATION PUBLICATIONS							<a href="#">Remove</a>	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button							<a href="#">Add</a>	
FOREIGN PATENT DOCUMENTS							<a href="#">Remove</a>	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button							<a href="#">Add</a>	
NON-PATENT LITERATURE DOCUMENTS							<a href="#">Remove</a>	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

1	ARGENTA, A., et al., "Deformation of superficial and deep abdominal tissues with application of a controlled vacuum", European Tissue Repair Society, Focus group meeting Topical Negative Pressure (TNP) Therapy, London UK (4-6 December 2003). WFU-55	<input type="checkbox"/>
2	ARGENTA, L., et al., "Vacuum assisted closure (VAC therapy) for secondary closure of dehisced and infected wounds", Wound Repair and Regeneration, (July-September, 1995), pp. 361; 5th Annual Meeting of the European Tissue Repair Society, Padova Italy, (1 page of abstract) (August 30-September 2, 1995). WFU-11	<input type="checkbox"/>
3	ARGENTA, L.C., et al., "Use of V.A.C. for treatment of dehisced sternal incisions", Plastic Surgical Forum, vol. XXIII, 69th Annual Scientific Meeting of the American Society of Plastic Surgeons..., Los Angeles, CA, pp. 172-174. (2 sheets of abstract.) (October 14-18, 2000). WFU-06	<input type="checkbox"/>
4	ARGENTA, L.C., et al., "The V.A.C. as an adjunct for treatment for abdominal wounds", 66th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons, San Francisco, CA, pp. 330-331; 1 sheet of abstract (September 21-24 1997). WFU-39	<input type="checkbox"/>
5	ARGENTA, L.C., et al., "Vacuum assisted closure of chronic wounds", 65th Annual Scientific Meeting, American Society of Plastic and Reconstructive Surgeons, Dallas, TX, pp. 226-227; 1 sheet of abstract (November 9-13, 1996). WFU-37	<input type="checkbox"/>
6	BANWELL, P., et al. eds., "Topical Negative Pressure TNP Focus Group Meeting", European Tissue Repair Society, Proceedings, London, UK 232 pp. (2003). WFU-24	<input type="checkbox"/>
7	BANWELL, P., et al., "Dermal perfusion in experimental partial thickness burns: the effect of topical subatmospheric pressure", January/February 2000, Burn Care & Rehabil., part 2, 21(1):S161, Proceedings of the American Burn Association, 32nd Annual Meeting, Las Vegas, Nevada (March 14-17, 2000). WFU-07	<input type="checkbox"/>
8	BANWELL, P.E., et al., "Application of topical sub-atmospheric pressure modulates inflammatory cell extravasation in experimental partial thickness burns", Wound Repair and Regen., 7(4):A287 (July/August 1999). WFU-08	<input type="checkbox"/>
9	DEFRANZO, A.J., et al., "109: Use of sub-atmospheric pressure for treatment of gunshot injuries", Plastic Surgical Forum, vol. XXIII, 69th Annual Scientific Meeting of the American Society of Plastic Surgeons..., Los Angeles, CA, pp. 180-181 (1 sheet of abstract) (October 14-18, 2000). WFU-05	<input type="checkbox"/>
10	DEFRANZO, A.J., et al., "The use of V.A.C. therapy for treatment of lower extremity wounds with exposed bone", 68th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons, New Orleans, LA, pp. 37-38; 2 sheets of abstract (October 24-27, 1999). WFU-42	<input type="checkbox"/>
11	KORTESIS, B., et al., "Vacuum-assisted closure for the treatment of open tibia fractures", 72nd Annual Meeting of the American Society of Plastic Surgeons, San Diego, CA, pp. 172-3; 1 sheet of abstract (October 25-29, 2003) WFU-41	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

12	KREMERS, L., et al., "Effect of topical sub-atmospheric pressure treatment on angiotensin I and II levels post burn", 35th Annual Meeting, Abstract printed in J. Burn Care Rehabilitation, page S44, Abstract no. 3 American Burn Association, Miami, Florida (April 1-4 2003). WFU-54	<input type="checkbox"/>
13	KREMERS, L., et al., "Serum interleukin levels post burn with and without application of sub-atmospheric pressure", 35th Annual Meeting, Abstract printed in Burn Care Rehabilitation, page S43, Abstract no. 2, American Burn Association, Miami, Florida, (April 1-4 2003). WFU-53	<input type="checkbox"/>
14	MARKS, M.W., et al., "Management of complex soft tissue defects in pediatric patients using the V.A.C. wound closure", Plastic Surgical Forum, vol. XXI, 67th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons..., Boston, MA, pp. 215-216 (October 3-7, 1998). WFU-09	<input type="checkbox"/>
15	MOLNAR, J.A., et al., "Improved skin graft adherence and vascularization of Integra(R) using subatmospheric pressure – a laboratory study", Abstract printed in Burn Care & Rehabilitation, page S111, Abstract no. 141; American Burn Meeting, 34th Annual Meeting, Chicago, IL, (April 24-27 2002). WFU-51	<input type="checkbox"/>
16	MORYKwas, M., et al., "Treatment of burned extremities using vacuum therapy (The V.A.C.)", Wound Repair and Regeneration, 3(3):367, (July – September, 1995), 5th Annual Meeting of the European Tissue Society, Padova, Italy, (August 30-September 2, 1995). WFU-15	<input type="checkbox"/>
17	MORYKwas, M.J., "The use of the V.A.C. wound treatment system for acute and subacute wounds", Plaies & Cicatrices, Wound Closure Healing, European Master Class in Wound Closure and Healing, Montpellier, France, (3pp.) (April 21, 22 and 23, 1999). WFU-17	<input type="checkbox"/>
18	MORYKwas, M.J., et al., "Isolated muscle flap survival with complete venous occlusion: varying delay in external application of sub-atmospheric pressure", Plastic Surgical Forum, Vol. XXI, 67th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons..., Boston, MA, pp. 237 (Oct. 3-7, 1998). WFU-16	<input type="checkbox"/>
19	MORYKwas, M.J., et al., "Sub-atmospheric pressure for the treatment of lower extremity wounds", The Third Riva Congress, Current Perspectives In Fracture Management and Orthopaedic Reconstruction, Riva del Garda, Italy, pp. 135-136, (May 10-14, 2000) WFU-18	<input type="checkbox"/>
20	MORYKwas, M.J., et al., "Use of negative pressure to increase the rate of granulation tissue formation in chronic open wounds", FASEB J. part I, Abstracts 1-3006, (Extracellular Matrix and Healing, 799-800) (Feb. 19, 1993), Experimental Biology '93, abstract no. 800, New Orleans, Louisiana, (March 28-April 1, 1993). WFU-13	<input type="checkbox"/>
21	MORYKwas, M.J., et al., "Use of negative pressure to prevent progression of partial thickness burns", American Burn Association, vol. 26, 26th Annual Meeting, Orlando, Florida, pp. 157 (April 20-23, 1994). WFU-14	<input type="checkbox"/>
22	MORYKwas, M.J., et al., "V.A.C. experience and difficult wounds," des Journees Regionales des Plaies et Cicatrisations", 2:76-90 (September 22-23, 1997). WFU-01	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

23	MORYKwas, M.J., et al., "Negative pressure treatment of burned extremities", 65th Annual Scientific Meeting, American Society of Plastic and Reconstructive Surgeons, Dallas, TX, pp. 86-87; 1 sheet of abstract (November 9-13, 1996). WFU-36	<input type="checkbox"/>
24	MORYKwas, M.J., et al., "The effect of V.A.C.(TM) therapy on the length of stay, total charges and average daily charge for patients assigned to DRG 263: analysis of 13 consecutive quarters", presented in part at the 28th Annual Conference of the Wound, Ostomy, and Continence Nurses Society, Seattle, WA, (15 sheets) (June 15-19, 1996). WFU-52	<input type="checkbox"/>
25	PARK, C.A., et al., "Outpatient use of Integra® and subatmospheric pressure in the management of wound and burn reconstruction", J. Burn Care Rehabil., 26(2 suppl.)S113, Chicago, IL, (May 10-13, 2005). WFU-62	<input type="checkbox"/>
26	SCHNEIDER, A.M., et al., "Muscle flap survival after complete venous occlusion by application of a negative pressure device", 66th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons, San Francisco, CA, pp. 300-302; 2 sheets of abstract (September 21-24 1997). WFU-38	<input type="checkbox"/>
27	SCHNEIDER, A.M., et al., "Treatment of brown recluse spider bite wounds by external application of sub-atmospheric pressure", 68th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons, New Orleans, LA, page 35; 1 sheet of abstract (October 24-27, 1999). WFU-40	<input type="checkbox"/>
28	WEBB, L.X., "Use of negative pressure devices in highly contaminated, high energy wounds", Extremity War Injuries: State of the Art and Future Directions, AAOS/OTA Extremity War Injuries Symposium, January 24-27, 2006. [Abstract]. WFU-65	<input type="checkbox"/>
29	WEBB, L.X., et al., "Negative pressure wound therapy in the management of orthopedic wounds", Ostomy Wound Management, 50(4A Suppl.)26-27, Supplement - Proceedings from the 2003 National V.A.C.™ Education Conference (April 2004). WFU-22	<input type="checkbox"/>
30	WEBB, L.X., et al., "The use of vacuum-assisted closure in composite wound management", The Third Riva Congress, Current Perspectives in Fracture Management and Orthopaedic Reconstruction, Riva del Garda, Italy, pp. 137 (May 10-14, 2000). WFU-20	<input type="checkbox"/>
31	MORYKwas, M.J., "Basic Research and Animal Studies," Presentation at the European Topical Negative Pressure Meeting in Salsbury, England, (June 2005). WFU-71	<input type="checkbox"/>
32	DEFRANZO, A.J., et al., "Vacuum assisted closure of the abdominal wall", 73rd Annual Meeting, American Association of Plastic Surgeons, Philadelphia, PA (2004), 1 sheet of abstract. WFU-60	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

**EXAMINER SIGNATURE**

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-06-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.  
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.  
 None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haun/	Date (YYYY-MM-DD)	2007-05-02
Name/Print	Niels Haun	Registration Number	48,488

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.